Adaptin Bio, Inc.
- Close
- Jun 29, 2026
- Market cap
- $55.38M
- 8.9M shares
- Filings
- 78
—
—
—Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
—
—
—Q3 2026N/M FY25 yoy
Q3 2026+1,247.1% FY25 yoy
- $55.38M
- —
- —
- —
- —
- —
FY2025 figures · derived
Price
Jun 29, 2026 · Official close
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Research And Development
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1,774,166 | reported | |
| FY 2024 | 2024-12-31 | $1,824,591 | reported |
Biological products, except diagnostic substances
Adaptin Bio, Inc. is the 122nd largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
CGTXCognition Therapeutics Inc———$64.5MGRMLGreenland Mines Ltd———$57.1MCRDFCardiff Oncology, Inc.$593.0K13.2%7,732.0%$56.8M
APTNAdaptin Bio, Inc. (this company)———$55.4M
ELOXEloxx Pharmaceuticals, Inc.$0.0100.0%—$52.1MINKTMiNK Therapeutics, Inc.———$49.8MSGMOQSangamo Therapeutics, Inc$39.6M31.6%310.8%$49.7MLONALeonaBio, Inc.———$49.2MTILInstil Bio, Inc.———$47.1MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Adaptin Bio, Inc. · CIK 1938571 · Engraved from SEC EDGAR